ABATA
Live / Allowed — Notice of allowance issued (as of 09 Sept 2025)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 18 Dec 2024 filing date already counts against anyone who files later.
Record
- Serial number
- 98909678
- Mark type
- Stylized text
- Filed
- 18 Dec 2024
- Published for opposition
- 15 Jul 2025
- Attorney of record
- Susan Piascik Christoff
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for cell therapy, namely pharmaceutical preparations for T cell therapy; pharmaceutical preparations and vaccines for use in gene therapy and cell therapy; biological preparations for use in medical and clinical gene therapy and cell therapy for the treatment of cancer, autoimmune diseases, neurological disorders, inflammatory conditions, transplant complications, and immunological disorders; pharmaceutical products for the prevention and treatment of cancer, autoimmune diseases, neurological disorders, inflammatory conditions, transplant complications, and immunological disorders; immunotherapy products, namely, pharmaceutical preparations for the treatment of cancer, autoimmune diseases, neurological disorders, inflammatory conditions, transplant complications, and immunological disorders; biological preparations for the treatment of cancer, autoimmune diseases, neurological disorders, inflammatory disorders, transplant complications, and immunological disorders; chemical and biochemical preparations for medical purposes, specifically, for the treatment and diagnosis of cancer, autoimmune diseases, neurological disorders, inflammatory conditions, transplant complications, and immunological disorders; biochemical, namely, monoclonal antibodies for medical purposes, specifically, for the treatment and diagnosis of cancer, autoimmune diseases, neurological disorders, inflammatory conditions, transplant complications, and immunological disorders
- Class 040 — Treatment of materials: Custom manufacture of therapeutic drugs, namely, custom manufacture of cell and gene therapies; custom manufacturing for others, namely, manufacturing of pharmaceutical preparations for health care, for the treatment of humans suffering from diseases treated by cell therapy or gene therapy or regenerative medicine products, more specifically medicines for human use as well as medicines for experimental medical and therapeutic uses, biological products for experimental purposes, preparations for cell therapy, gene therapy, and medicines for innovative therapies
Owner
- Abata Therapeutics, Inc., Watertown, MA, US
- Abata Therapeutics, Inc., Watertown, MA, US
Prosecution history
- 09 Sept 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 15 Jul 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 15 Jul 2025 — PUBLISHED FOR OPPOSITION
- 09 Jul 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 09 Jun 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 04 Jun 2025 — ASSIGNED TO EXAMINER
- 27 Apr 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 18 Dec 2024 — NEW APPLICATION ENTERED